OncoHost announced that its CLIA-certified proteomics laboratory in Cary, North Carolina, has received accreditation from the College of American Pathologists (CAP).
Central to OncoHost's approach is its proprietary PROphet platform, a plasma-based proteomic pattern recognition tool that combines systems biology, bioinformatics, and artificial intelligence to support clinical decision-making. Requiring only a single pre-treatment blood sample, PROphet analyzes patterns across approximately 7,000 proteins to generate a PROphet score—a clinically validated metric that reflects a patient’s likelihood of clinical benefit. This insight allows for effective and personalized treatment decisions, supporting patient-specific plans based on the unique biology of each individual.
OncoHost’s Cary lab demonstrated full compliance with CAP’s standards across areas such as quality control, safety, personnel qualifications, equipment maintenance, and operational management.
